NEW YORK (GenomeWeb News) – Qiagen said yesterday that it has signed a definite agreement to acquire SABiosciences, a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels, for $90 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.